This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Swissmed Centrum Zdrowia Valuation

Q: What is the Fair Price of SWD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SWD (PLN10.9) is trading above our estimate of [[fair value]] (PLN3.61)

Is SWD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SWD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SWD (PLN10.9) is trading above our estimate of fair value (PLN3.61)

Significantly Below Fair Value: SWD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SWD?

Key metric: As SWD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SWD. This is calculated by dividing SWD's market cap by their current revenue.
What is SWD's PS Ratio?
PS Ratio	1.7x
Sales	zł39.49m
Market Cap	zł66.69m

SWD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.6x
Enterprise Value/EBITDA	57.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SWD's PS Ratio compare to its peers?

The above table shows the PS ratio for SWD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.8x
EMC EMC Instytut Medyczny	0.7x	n/a	zł436.9m
ENE Centrum Medyczne ENEL-MED	0.8x	n/a	zł562.8m
CRM PZ Cormay	0.5x	n/a	zł39.6m
BMX BioMaxima	1.2x	n/a	zł59.1m
SWD Swissmed Centrum Zdrowia	1.7x	n/a	zł66.7m

Price-To-Sales vs Peers: SWD is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (85.2x).

Price to Sales Ratio vs Industry

How does SWD's PS Ratio compare vs other companies in the European Healthcare Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SWD is expensive based on its Price-To-Sales Ratio (1.7x) compared to the Polish Healthcare industry average (1x)

Price to Sales Ratio vs Fair Ratio

What is SWD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SWD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SWD's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.